Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Early tuberculosis treatment monitoring by Xpert® MTB/RIF

Paolo Miotto, Sara Bigoni, Giovanni Battista Migliori, Alberto Matteelli, Daniela M. Cirillo
European Respiratory Journal 2012 39: 1269-1271; DOI: 10.1183/09031936.00124711
Paolo Miotto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Bigoni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giovanni Battista Migliori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto Matteelli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela M. Cirillo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cirillo.daniela@hsr.it
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editors:

Progress made to improve laboratory capacity for tuberculosis (TB) diagnosis led to the development of molecular assays that are now replacing conventional microscopy and culture-based methods on a large scale [1, 2]. Unfortunately, current molecular techniques detect both live and dead bacteria, and a positive result does not imply the viability of the pathogen. Indeed, DNA can persist for a long period after bacterial death and nucleic acid from dead bacteria is equally amplifiable. Therefore, molecular assays are unsuitable for treatment monitoring and/or for infection control purposes.

We report an innovative approach to selectively amplify DNA derived from viable Mycobacterium tuberculosis in clinical specimens, which is useful for monitoring mycobacterial load in pulmonary TB patients during anti-TB treatment.

The protocol is based on pre-treatment of samples with propidium monoazide (PMA; Biotium Inc., Hayward, CA, USA), a chemical compound that can intercalate the DNA of non-viable (or membrane-damaged) organisms but is excluded from viable bacteria. After light activation, PMA binds covalently to the DNA, preventing its amplification by PCR [3]. After light exposure, unbound PMA is not able to interact further with DNA molecules.

The assay was first optimised using acid-fast bacilli (AFB)-negative sputum samples spiked with dead or live mycobacteria at different concentrations. In brief, live Mycobacterium fortuitum cells were added to N-acetyl-cysteine decontaminated sputum specimens negative for AFB by smear microscopy at a final concentration of 106 bacteria·mL−1. An aliquot of this laboratory-made sample was treated to heat kill the M. fortuitum cells. PMA stock solution was prepared and stored at -20°C and protected from light exposure, until use, as recommended by the manufacturers. PMA was added as a pre-treatment at a final concentration of 500 μM and incubated for 30 min at 4°C in the dark, followed by light exposure to blue light-emitting diode (LED)-active light (GenIUL, Terrassa, Spain) for 15 min at room temperature. DNA was then extracted using a standard phenol chloroform procedure. As a control to evaluate the efficacy of the light exposure step, an aliquot of naked DNA extracted from an M. fortuitum culture was treated with 500 μM PMA previously exposed to the LED light for 15 min. The commercial line-probe assay (GenoType® Mycobacterium CM; Hain Lifescience, Nehren, Germany) was then performed in order to identify clinically relevant mycobacterial species [4]. Samples containing live M. fortuitum showed a normal hybridisation profile on a nitrocellulose strip, whereas samples treated to kill bacteria did not show any amplification, except for the internal control (data not shown). Since naked DNA treated with light-inactivated PMA showed a normal hybridisation profile, the light exposure step was efficient and the PCR was not further inhibited by residual PMA.

Having optimised the protocol for the inactivation of DNA derived from dead bacteria, we adapted it to the Xpert® MTB/RIF automated assay (Cepheid, Sunnyvale, CA, USA). The real-time PCR performed by the Xpert® MTB/RIF provides threshold cycles (Ct) that can be used to calculate the difference in amplification yield between samples with and without PMA pre-treatment (ΔCt): a low ΔCt indicates the presence of amplifiable DNA from live bacteria, whereas a high ΔCt indicates that target DNA in the sample originated from dead or damaged bacteria and, therefore, PMA pre-treatment significantly affects its amplification. To calculate the ΔCt value we considered the mean between the Ct values provided for each probe included in the Xpert® MTB/RIF test (A to E) [5].

We tested the PMA protocol using the Xpert® MTB/RIF assay on a Ct calibration curve of AFB-negative clinical specimens with heat-killed/live mycobacteria added in different ratios. High dead–live ratios resulted in a maximal difference in ΔCt values between heat-treated and live portions with PMA, whereas samples containing a similar percentage of killed and live bacteria could not be differentiated from one another by the use of PMA pre-treatment (data not shown). Similar data have been reported by Kralik et al. [6].

Finally, we tested the approach on clinical specimens. 10 patients diagnosed with active pulmonary TB (sputum smear positive and culture positive) were included in the first validation study. Samples were collected at the time of diagnosis (t0) and after 10–20 days of therapy (t1), N-acetyl-cysteine decontaminated and processed for MGIT-960 liquid culture (BD Diagnostic Systems, Sparks, MD, USA) according to international guidelines [7]. All patients were still AFB-positive by sputum smear microscopy at t1. In parallel, 250 μL of decontaminated samples were processed for molecular analysis by Xpert® MTB/RIF assay with and without PMA pre-treatment. Samples were then processed as recommended by the manufacturer's instructions for the Xpert® MTB/RIF assay.

As shown in figure 1, PMA did not significantly affect PCR yield of specimens collected at t0 (mean±sem ΔCt 2.3±0.5), whereas specimens collected during therapy at t1 showed a ΔCt of 10.5±0.9 after PMA treatment (p=0.0003) confirming that the sputum smear positivity of these samples was mostly due to highly damaged bacteria. Moreover, ΔCt calculated between t0 and t1 in PMA-untreated samples was found to be too low (ΔCt 2.9±0.9) to appreciate a real decrease in bacterial load due to the therapy.

Figure 1–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1–

Comparison between the mean difference in threshold cycle (ΔCt) (propidium monoazide (PMA) treated minus PMA untreated) obtained from sputum samples collected before starting treatment (t0) and 10–20 days after the beginning of anti-tuberculosis therapy (t1). Errors bars represent ± sem values. ***: p<0.001.

Two patients rated “low” at t0 by the Xpert® showed a negative culture at t1, whereas all the other patients rated “medium” or “high” remained culture positive by MGIT. Although an exact time to positivity cannot be assessed, we observed that cultures from samples collected at t1 became positive approximately 7–10 days later compared with cultures from samples collected at t0, suggesting a severe reduction in the live bacterial load.

All patients were successfully treated and cured at the end of therapy, and this was consistent with the reduction of live bacteria detected by the PMA assay.

As a negative control, we retrospectively also included a treatment failure case (AFB positive and culture positive after 5 months of standard treatment). In this case, PMA pre-treatment of both decontaminated sputum specimens collected at 1 month and two during treatment did not significantly affect PCR yield (ΔCt ∼2), thus supporting inefficacy of anti-TB treatment.

The same protocol should, in principle, be compatible with other CE-approved molecular tests and line probe assays endorsed by the World Health Organization for the diagnosis of TB; further studies are needed to rule out this possibility.

Previous studies [3, 6] have demonstrated the possibility of using PMA to distinguish between live and dead mycobacteria using a concentration of 25–50 μM. During protocol set up, a final concentration of 100 μM fully avoided amplification of DNA derived from heat-killed M. fortuitum; a weak background due to the amplification of DNA from heat-killed M. tuberculosis was observed (data not shown). We can speculate that the different cell wall composition somehow affects the capacity of PMA to penetrate damaged mycobacteria. Indeed, Kralik et al. [6] observed that the PMA-induced signal reduction between live and dead Mycobacterium avium subsp. paratuberculosis were lower compared with those found for other bacterial species. In addition, considering the amount of debris that could potentially sequester PMA molecules in decontaminated sputa, we increased the final concentration to 500 μM. Further studies evaluating differences of PMA treatment effect on strains showing different cell wall composition (e.g. Beijing strains) and/or in sputa with different characteristics (e.g. blood-containing sputum) could better elucidate the usefulness of this test in different clinical settings.

According to LØvdal et al. [8], a small proportion of cells presumed to be dead or heavily injured are not able to grow. The presence of a small number of cells that are heavily injured but non-culturable could explain why we still have a positive signal in samples collected at t1 despite the PMA pre-treatment. PMA pre-treatment does not avoid the detection of a small proportion of dead cells (false positive for a viability assay): the test might, therefore, overestimate viable mycobacteria. However, from a clinical perspective, this would represent a minor error compared with the risk (very small for this test) of underestimating viable mycobacteria.

Our data indicate, for the first time, that quantitative molecular techniques combined with the PMA method could be an alternative to direct microscopy and culture for monitoring early treatment response and for preliminary evaluation of personalised regimens. The use of this assay can allow earlier evaluation of treatment efficacy, showing a clear decrease in the vital mycobacterial load. However, the absence of the response to therapy might also be promptly identified by the test allowing a regimen change and limiting the spread of infection and further resistance development [9].

Footnotes

  • Support Statement

    The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement FP7-223681 awarded to D.M. Cirillo.

  • Statement of Interest

    None declared.

  • ©ERS 2012

REFERENCES

  1. ↵
    1. Ling DI,
    2. Zwerling AA,
    3. Pai M
    . GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32: 1165–1174.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Boehme CC,
    2. Nicol MP,
    3. Nabeta P,
    4. et al
    . Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377: 1495–1505.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Nocker A,
    2. Cheung CY,
    3. Camper AK
    . Comparison of propidium monoazide with ethidium monoazide for differentiation of live vs. dead bacteria by selective removal of DNA from dead cells. J Microbiol Methods 2006; 67: 310–320.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Russo C,
    2. Tortoli E,
    3. Menichella D
    . Evaluation of the new GenoType Mycobacterium assay for identification of mycobacterial species. J Clin Microbiol 2006; 44: 334–339.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    World Health Organization. Report of the Tenth Meeting WHO Strategic and Technical Advisory Group for Tuberculosis (STAG-TB) 27–29 September 2010. WHO/HTM/TB/2010.18. Geneva, World Health Organization, 2010.
  6. ↵
    1. Kralik P,
    2. Nocker A,
    3. Pavlik I
    . Mycobacterium avium subsp. paratuberculosis viability determination using F57 quantitative PCR in combination with propidium monoazide treatment. J Food Microbiol 2010; 141: Suppl. 1, S80–S86.
    OpenUrlCrossRef
  7. ↵
    World Health Organization: Laboratory Services in Tuberculosis Control–Culture Part III. WHO/TB/98.258. Geneva, World Health Organization, 1998.
  8. ↵
    1. Løvdal T,
    2. Hovda MB,
    3. Björkblom B,
    4. et al
    . Propidium monoazide combined with real-time quantitative PCR underestimates heat-killed Listeria innocua. J Microbiol Methods 2011; 85: 164–169.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Falzon D,
    2. Jaramillo E,
    3. Schünemann HJ,
    4. et al
    . WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516–528.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 39 Issue 5 Table of Contents
European Respiratory Journal: 39 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Early tuberculosis treatment monitoring by Xpert® MTB/RIF
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Early tuberculosis treatment monitoring by Xpert® MTB/RIF
Paolo Miotto, Sara Bigoni, Giovanni Battista Migliori, Alberto Matteelli, Daniela M. Cirillo
European Respiratory Journal May 2012, 39 (5) 1269-1271; DOI: 10.1183/09031936.00124711

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Early tuberculosis treatment monitoring by Xpert® MTB/RIF
Paolo Miotto, Sara Bigoni, Giovanni Battista Migliori, Alberto Matteelli, Daniela M. Cirillo
European Respiratory Journal May 2012, 39 (5) 1269-1271; DOI: 10.1183/09031936.00124711
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Predictors of treatment outcome in MDR-TB in Portugal
  • Drug concentration in lung tissue in MDR-TB
  • Obesity in COPD: the effect of water-based exercise
Show more Letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society